KDR and renal cell carcinoma: Additionally, while the number of patients in randomized trials for pRCC vs. ccRCC is already low and the number of black vs. white patients in trials for RCC is even lower, multi-institutional efforts to pool data should be undertaken to analyze whether trials utilizing VEGFR therapies are producing a favorable response in black patients with advanced pRCC.